TY - JOUR
T1 - Effects of Repeated Co-Injections of Corticosteroids and Hyaluronic Acid on Knee Osteoarthritis
T2 - A Prospective, Double-Blind Randomized Controlled Trial
AU - Wang, Chun Ping
AU - Lee, Wen Chung
AU - Hsieh, Ru Lan
N1 - Copyright © 2021 Elsevier Inc. All rights reserved.
PY - 2022/5
Y1 - 2022/5
N2 - Background: We compared the effects of repeated co-injections of corticosteroids plus hyaluronic acid (HA) with the effects of HA injections alone in patients with knee osteoarthritis. Methods: A double-blind randomized controlled trial was conducted between October 2016 and July 2017 at a medical center. Patients (n = 57) who fulfilled the clinical and radiographic criteria for knee osteoarthritis established by the American College of Rheumatology with a Kellgren-Lawrence score of 2 or 3 were included. They were assigned to either the HA group (n = 29) or corticosteroids plus HA group (n = 28), and injections were administered under ultrasound guidance once a week for 3 consecutive weeks. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores were the primary outcomes. Physical functional performance (10-m fast walking and chair-rising time) and the Knee Injury and Osteoarthritis Outcome Score (KOOS) were secondary outcomes. The assessment was performed prior to injections, 1 week, and 1, 3, and 6 months after injections. Data were analyzed through repeated-measures analysis of covariance. Results: Both groups experienced decreased pain and improved physical function and physical functional performance over time. We found significant group × time interaction effects favoring the corticosteroids plus HA group in WOMAC-pain (P = .005) and physical function (P = .005), chair-rising time (P = .032), and KOOS-pain (P = .001). Conclusions: Repeated co-injections of corticosteroids plus HA more effectively decreased pain and improved physical function and physical functional performance than injections of HA alone from 1 week through 6 months posttreatment.
AB - Background: We compared the effects of repeated co-injections of corticosteroids plus hyaluronic acid (HA) with the effects of HA injections alone in patients with knee osteoarthritis. Methods: A double-blind randomized controlled trial was conducted between October 2016 and July 2017 at a medical center. Patients (n = 57) who fulfilled the clinical and radiographic criteria for knee osteoarthritis established by the American College of Rheumatology with a Kellgren-Lawrence score of 2 or 3 were included. They were assigned to either the HA group (n = 29) or corticosteroids plus HA group (n = 28), and injections were administered under ultrasound guidance once a week for 3 consecutive weeks. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores were the primary outcomes. Physical functional performance (10-m fast walking and chair-rising time) and the Knee Injury and Osteoarthritis Outcome Score (KOOS) were secondary outcomes. The assessment was performed prior to injections, 1 week, and 1, 3, and 6 months after injections. Data were analyzed through repeated-measures analysis of covariance. Results: Both groups experienced decreased pain and improved physical function and physical functional performance over time. We found significant group × time interaction effects favoring the corticosteroids plus HA group in WOMAC-pain (P = .005) and physical function (P = .005), chair-rising time (P = .032), and KOOS-pain (P = .001). Conclusions: Repeated co-injections of corticosteroids plus HA more effectively decreased pain and improved physical function and physical functional performance than injections of HA alone from 1 week through 6 months posttreatment.
KW - Adrenal Cortex Hormones/therapeutic use
KW - Double-Blind Method
KW - Humans
KW - Hyaluronic Acid/therapeutic use
KW - Injections, Intra-Articular
KW - Osteoarthritis, Knee/complications
KW - Pain/drug therapy
KW - Prospective Studies
KW - Treatment Outcome
UR - http://www.scopus.com/inward/record.url?scp=85125993412&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125993412&partnerID=8YFLogxK
U2 - 10.1016/j.amjmed.2021.11.016
DO - 10.1016/j.amjmed.2021.11.016
M3 - Article
C2 - 34958762
AN - SCOPUS:85125993412
SN - 0002-9343
VL - 135
SP - 641
EP - 649
JO - American Journal of Medicine
JF - American Journal of Medicine
IS - 5
ER -